SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Cleland W)
 

Search: WFRF:(Cleland W) > (2005-2009) > Exchange of beta-bl...

Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)

Di Lenarda, A. (author)
Remme, W. J. (author)
Charlesworth, A. (author)
show more...
Cleland, J. G. (author)
Lutiger, B. (author)
Metra, M. (author)
Komajda, M. (author)
Torp-Pedersen, C. (author)
Scherhag, A. (author)
Swedberg, Karl, 1944 (author)
Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Cardiovascular Institute
Poole-Wilson, P. A. (author)
show less...
 (creator_code:org_t)
2005-05-28
2005
English.
In: European journal of heart failure. - : Wiley. - 1388-9842. ; 7:4, s. 640-9
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • BACKGROUND: The Carvedilol or Metoprolol European Trial (COMET) reported a significant survival benefit for carvedilol, a beta1-, beta2- and alpha1-blocker, vs. metoprolol tartrate, a beta1-selective blocker, in patients with mild-to-severe chronic heart failure (CHF). Patients on treatment with metoprolol might benefit from switching to carvedilol. AIM: To investigate the safety and tolerability of switching beta-blockers in CHF. METHODS: At the end of COMET, the Steering Committee recommended that study medication was stopped without unblinding, and patients were commenced on open-label beta-blockade at a dose equivalent to half the dose of blinded therapy, with subsequent titration to target or maximum tolerated dose. Patients were followed for 30 days. RESULTS: 1321 out of 1440 patients were transitioned to open-label treatment (76.8% to carvedilol). Serious adverse and CHF-related events were respectively 9.4% and 4.7% in those switching from carvedilol to metoprolol and 3.1% and 1.5% in patients switching from metoprolol to carvedilol. Patients who switched from carvedilol to metoprolol showed the highest mortality or hospitalisation rate (12.3%) in comparison with those who switched from metoprolol to carvedilol (3.1%, p<0.001) or who stayed on the same drug (carvedilol: 2.5%, p<0.001; metoprolol: 4.2%, p=0.04). Reducing the initial dose of the second beta-blocker maximised the safety of this strategy. Event rate was higher in patients with more severe heart failure and in those withdrawing from beta-blockade. CONCLUSION: Our data show that switching beta-blockers is a practical, safe and well-tolerated strategy to optimise treatment of CHF. Patients who switched to carvedilol showed the lowest rate of adverse events. A closer clinical monitoring is recommended during transition in high-risk patients.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Kardiologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)

Keyword

dosage/pharmacology/*therapeutic use
Aged
Blood Pressure/drug effects
Carbazoles/administration & dosage/pharmacology/*therapeutic use
Female
Heart Failure
Congestive/*drug therapy
Heart Rate/drug effects
Humans
Male
Metoprolol/administration & dosage/pharmacology/*therapeutic use
Middle Aged
Propanolamines/administration & dosage/pharmacology/*therapeutic use
Randomized Controlled Trials
Treatment Outcome

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view